Dermata Therapeutics (DRMA) Non-Current Deferred Tax Liability (2022 - 2024)

Dermata Therapeutics' Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $2.6 million for Q4 2024.

• In Q4 2024, Non-Current Deferred Tax Liability rose 73.47% year-over-year to $2.6 million; the TTM figure through Dec 2024 stood at $2.6 million (up 73.47% YoY), while the FY2024 annual figure was $2.6 million, up 73.47% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2024 stood at $2.6 million, up from $18000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $2.6 million in Q4 2024, with the low at $18000.0 in Q3 2024.
• The 3-year median for Non-Current Deferred Tax Liability is $580449.5 (2022), against an average of $888405.5.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability surged 41.2% in 2023, then surged 73.47% in 2024.
• Dermata Therapeutics' Non-Current Deferred Tax Liability stood at $1.1 million in 2022, then soared by 41.2% to $1.5 million in 2023, then soared by 73.47% to $2.6 million in 2024.
• Business Quant data shows DRMA's Non-Current Deferred Tax Liability at $2.6 million in Q4 2024, $18000.0 in Q3 2024, and $27534.0 in Q2 2024.